Marker Therapeutics, Inc is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Marker Therapeutics employs 44 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Marker Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MRKR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Marker Therapeutics stock price (NASDAQ: MRKR)Use our graph to track the performance of MRKR stocks over time.
Marker Therapeutics shares at a glance
|Latest market close||$2.91|
|52-week range||$1.32 - $3.65|
|50-day moving average||$2.78|
|200-day moving average||$2.49|
|Wall St. target price||$6.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.17|
Buy Marker Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Marker Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Marker Therapeutics price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||3.93%|
|3 months (2021-04-30)||13.67%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Marker Therapeutics financials
|Gross profit TTM||$-18,413,966|
|Return on assets TTM||-29.55%|
|Return on equity TTM||-55.36%|
|Market capitalisation||$181.8 million|
TTM: trailing 12 months
Shorting Marker Therapeutics shares
There are currently 965,491 Marker Therapeutics shares held short by investors – that's known as Marker Therapeutics's "short interest". This figure is 21.8% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Marker Therapeutics shares can be evaluated.
Marker Therapeutics's "short interest ratio" (SIR)
Marker Therapeutics's "short interest ratio" (SIR) is the quantity of Marker Therapeutics shares currently shorted divided by the average quantity of Marker Therapeutics shares traded daily (recently around 1.0 million). Marker Therapeutics's SIR currently stands at 0.94. In other words for every 100,000 Marker Therapeutics shares traded daily on the market, roughly 940 shares are currently held short.
However Marker Therapeutics's short interest can also be evaluated against the total number of Marker Therapeutics shares, or, against the total number of tradable Marker Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marker Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Marker Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0162% of the tradable shares (for every 100,000 tradable Marker Therapeutics shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Marker Therapeutics.
Find out more about how you can short Marker Therapeutics stock.
Marker Therapeutics share dividends
We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.
Have Marker Therapeutics's shares ever split?
Marker Therapeutics's shares were split on a 1:12 basis on 15 September 2016. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.
Marker Therapeutics share price volatility
Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $1.32 up to $3.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.2405. This would suggest that Marker Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Marker Therapeutics overview
Marker Therapeutics, Inc. , a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Stocks similar to Marker Therapeutics
Marker Therapeutics in the news
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
Frequently asked questionsWhat percentage of Marker Therapeutics is owned by insiders or institutions?
Currently 19.957% of Marker Therapeutics shares are held by insiders and 33.682% by institutions. How many people work for Marker Therapeutics?
Latest data suggests 44 work at Marker Therapeutics. When does the fiscal year end for Marker Therapeutics?
Marker Therapeutics's fiscal year ends in December. Where is Marker Therapeutics based?
Marker Therapeutics's address is: Phoenix Tower, Houston, TX, United States, 77027 What is Marker Therapeutics's ISIN number?
Marker Therapeutics's international securities identification number is: US57055L1070 What is Marker Therapeutics's CUSIP number?
Marker Therapeutics's Committee on Uniform Securities Identification Procedures number is: 57055L107
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert